AccuRna is pre-clinical stage Biotech Company based in Tokyo. The company has two types of novel proprietary drug delivery technologies for nucleic acid therapeutics known as unit Poly Ion Complex (uPIC) for short chain RNA and Polyplex micelle for long chain RNA. Those technologies have been invented by our scientific founder Professor Dr. Kazunori Kataoka, Project Professor of Policy Alternatives Research Institute at the University of Tokyo, Director General at Innovation Center of NanoMedicine (iCOMN). We have two internal pre-clinical development oncology programs, i.e. PRDM14 siRNA and TUG1 ASO. The former project will proceed to First-in-human Phase 1 study in 4Q 2019. AccuRna is seeking collaboration partners who could make the best use of our drug delivery technologies for their R & D effort on RNA therapeutics.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
PRDM14 siRNA with uPIC drug delivery system
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):